Summary:
- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su ch investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Neoleukin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information ab...
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal securities laws. On January 8, 2021, Neoleukin announced that "on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, ...
NEW YORK, NY / ACCESSWIRE / January 23, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ:NLTX).
NEW YORK, NY / ACCESSWIRE / January 14, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ:NLTX).
Neoleukin Therapeutics (NASDAQ: NLTX), a clinical-stage biopharmaceutical company, is not ending the week on a positive note. The catalyst for these losses is the company's announcement that it has received a Clinical Hold Letter from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for one of its pipeline candidates, NL-201. Before starting human clinical trials for their experimental medicines, drugmakers must submit an IND application and receiv...
Neoleukin Therapeutics Inc said on Friday the U.S. Food and Drug Administration has put on hold the drug developer's application to start human trials of its protein-based candidate, NL-201, to treat cancer. "We will be able to develop the requested assay and respond within the next several months," said Jonathan Drachman, chief executive officer. The company's lead treatment is a cancer immunotherapy, designed to expand cancer-fighting CD8 T-cells and natural killer cells.
SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.The FDA has informed Neo...
SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:30 p.m. Eastern Time. A live audio webcast of the corporate presentation and question and answer session ...